Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
We conducted a cohort study to examine the association between anticholinergic use and CVEs in a cohort with newly diagnosed COPD. In our study, we found an increased risk of CVE associated with the ...
Patients taking ipratropium bromide, an anticholinergic used in the treatment of COPD, may be at an increased risk for cardiovascular events (CVE), including heart failure. Patients taking ipratropium ...
RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...
Global pharma major Lupin Limited (Lupin) announced the launch of ipratropium bromide nasal solution (nasal spray), 0.03% and 0.06%, in the United States. Ipratropium bromide nasal solution (nasal ...
We used national Veteran's Health Administration health-care databases for this analysis, including inpatient and outpatient data, pharmacy data, and vital status information. The cohort in this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback